OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for Global Markets

OneSource Specialty Pharma Limited and Xbrane Biopharma AB have announced a partnership focused on the commercial manufacturing of Xbrane’s biosimilar portfolio. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference products. The lead candidate, Ximluci, is a ranibizumab biosimilar that has been granted market authorization approval in Europe and is under the approval process for the U.S. launch. As part of the agreement, Xbrane will tech transfer its select product(s) to OneSource’s state-of- the-art integrated Drug Substance and Drug Product (DS/DP) facility in Bangalore, India. The collaboration aims to strengthen Xbrane’s global supply chain, while enabling OneSource to accelerate regulatory approvals for its biologics drug substance facility. OneSource has also participated in Xbrane’s latest funding round.